Northstrive Fund II LP and Braeden Lichti Exit Position in Bluejay Diagnostics, Inc. (BJDX)

On June 2, 2026, Northstrive Fund II LP and Braeden Lichti filed Amendment No. 1 to their Schedule 13D regarding Bluejay Diagnostics, Inc. (BJDX). This filing serves as the final amendment and an exit filing for the reporting persons. Since the initial Schedule 13D filing on March 11, 2026, the reporting persons have disposed of all previously held shares of the Issuer's common stock. As of the event date, June 2, 2026, Northstrive Fund II LP and Mr. Lichti (who serves as the Manager of the fund) no longer beneficially own any shares of Bluejay Diagnostics, Inc., reducing their ownership percentage to 0.00%. The reporting persons have ceased to be beneficial owners of more than five percent of the Issuer’s outstanding Common Stock. No additional securities were acquired between the initial filing and this final disposition. This concludes their reporting obligations for this security.